Solution Development: A Model For Structuring Biotechs And Developing Better Drugs

The biopharma industry must think differently about funding high-risk/reward development of drug candidates against novel targets. Multiplexing Phase II proof-of-concept trials can light a path toward lower-risk pivotal studies and provide a model for building biotechs to deliver what patients, providers, payors, and investors all want: solutions.

The drug companies that have the hardest time raising capital to fund proof-of-concept research are the ones developing drugs against new targets. The irony is that in an industry that ostensibly strives to be innovative, investors hate risk and would prefer to invest in a reformulated (e.g., Alkermes PLC), repositioned (e.g., Cypress Bioscience Inc.), geographically relocated (e.g., Amarin Corp. PLC), relaunched (e.g., ViroPharma Inc.) or repriced drug (e.g., Questcor Pharmaceuticals Inc.) or enzyme replacement therapy NCE (e.g., Synageva BioPharma Corp.). These companies and others are successes in their own right but too exceptional to serve as role models for how our industry can continue to tackle large unmet healthcare needs in the coming decades. Such companies can raise money for a single validated agent; in fact, investors typically prefer that they focus on advancing one drug through later-stage trials and not divert any cash to an early-stage pipeline. (See Also see "How To Create A Lasting Peace Between Biotech Management, Shareholders And Employees" - In Vivo, 1 July, 2011..)

Yet it is likely that only innovative but riskier approaches can lift industry out of its current doldrums, providing the necessary advantages over current standards that will convince payors to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

AI In Drug Discovery: The Patent Implications

 
• By 

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By 

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

Laying The Foundation And Overcoming Prerequisites To Establish AI Within Health Care

 
• By 

As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.

Aurion Biotech’s Ophthalmic Cell Therapy For The Masses

 
• By 

Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.

More from In Vivo

US Health System Redesign Critical, NAM’s Medical Experts Warn Trump Government

 
• By 

The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.

Podcast: “Powerful Yet Unexplored”: Commit Biologics Tackles The Complement System

 

Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.

ML-Assisted Genetic Risk Score Predicts GLP-1 Adverse Events

 
• By 

Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.